Gilead and Merck's Weekly HIV Pill Successfully Suppresses Virus in Late-Stage Clinical Trials

What's Happening

Gilead Sciences and Merck & Co. have announced that their once-weekly oral HIV treatment successfully met the primary goals of two Phase 3 clinical trials, marking a significant milestone in the effort to reduce the burden of daily HIV medication.

The investigational regimen combines Gilead's lenacapavir with Merck's islatravir, allowing people living with HIV to take one pill once a week instead of daily antiretroviral therapy. In both late-stage studies, the weekly treatment was found to be non-inferior to standard daily oral regimens, meaning it controlled the virus just as effectively.

The companies plan to submit the data to global regulatory authorities, including the U.S. Food and Drug Administration (FDA), seeking approval for what could become the first once-weekly oral treatment for HIV.

How HIV Treatment Works Today

Modern HIV treatment relies on antiretroviral therapy (ART), which prevents the virus from multiplying inside the body.

Most patients currently take medication once every day, allowing them to:

• Suppress the virus to undetectable levels.
• Protect their immune system.
• Prevent progression to AIDS.
• Eliminate the risk of sexually transmitting HIV when viral suppression is maintained.

Daily therapy has transformed HIV from a fatal disease into a manageable chronic condition. However, maintaining lifelong adherence remains challenging for some patients.

Missing doses can allow the virus to replicate, increasing the risk of drug resistance and treatment failure.

Why a Weekly Pill Could Be Important

Researchers have spent years developing longer-acting HIV therapies to reduce the frequency of treatment.

Instead of taking medication every day, patients could potentially take:

• A weekly pill.
• Monthly injections.
• Every-two-month injections.
• Even longer-acting therapies currently under development.

A once-weekly pill could make treatment more convenient for many people by reducing the number of doses from 365 per year to just 52.

Improved convenience may help some patients maintain consistent treatment, particularly those who struggle with daily medication schedules.

About the Clinical Trials

The Phase 3 program evaluated the weekly regimen in adults whose HIV was already well controlled on existing therapy.

The studies compared:

• Once-weekly lenacapavir plus islatravir.
• Standard once-daily oral HIV treatment.

Researchers found that patients receiving the weekly regimen maintained viral suppression at rates comparable to those receiving daily treatment, achieving the studies' primary endpoint of non-inferiority. The safety profile was also generally consistent with previous studies of the medicines.

The companies indicated that detailed clinical data will be presented at future scientific meetings and included in regulatory submissions.

The Medicines Behind the Regimen

The investigational treatment combines two medicines with different mechanisms of action.

Lenacapavir: Developed by Gilead Sciences, lenacapavir is a capsid inhibitor, a newer class of HIV medicine that interferes with the virus's protective outer shell, preventing multiple stages of viral replication. Lenacapavir is already approved in several countries for certain patients with multidrug-resistant HIV and is also being studied for HIV prevention.

Islatravir: Merck's islatravir belongs to a newer generation of nucleoside reverse transcriptase inhibitors. Although its development was temporarily paused several years ago because of safety concerns observed at higher doses, Merck resumed development using lower doses after additional research supported an acceptable safety profile.

Together, the two medicines are designed to maintain effective antiviral activity over an entire week.

What Happens Next?

With successful Phase 3 results, Gilead and Merck plan to submit the once-weekly regimen for regulatory review.

Regulators will evaluate:

• Clinical effectiveness.
• Long-term safety.
• Manufacturing quality.
• Overall benefit-risk profile.

If approved, the therapy would become one of the first oral HIV treatments requiring only weekly dosing.

The companies have not yet announced an expected launch timeline, which will depend on the outcome of regulatory reviews.

Industry Impact

• Pharmaceutical Companies: The results reinforce the industry's growing focus on developing long-acting therapies that improve convenience while maintaining clinical effectiveness.
• Healthcare Providers: Clinicians may soon have another treatment option for patients who prefer oral therapy but find daily medication challenging.
• People Living With HIV: A weekly pill could simplify treatment routines and potentially improve long-term adherence for some patients while maintaining viral suppression.
• HIV Research: The successful trials demonstrate continued innovation beyond traditional daily therapies, with researchers exploring multiple approaches to reduce treatment frequency.

Why This Matters

The successful Phase 3 trials represent another important step in the evolution of HIV treatment.

Over the past three decades, advances in antiretroviral therapy have dramatically improved survival and quality of life for people living with HIV. The next frontier is making treatment easier to maintain over a lifetime.

Long-acting therapies—including injectable medicines and now potentially weekly oral treatments—aim to reduce treatment burden without compromising effectiveness. By decreasing the number of doses patients need to take, these therapies may improve adherence, reduce missed doses, and help sustain long-term viral suppression.

If approved, the Gilead-Merck regimen would provide patients and healthcare providers with an additional treatment option that bridges the gap between daily pills and long-acting injections.

Key Takeaways

• Gilead and Merck's once-weekly oral HIV regimen successfully met the primary endpoints of two Phase 3 clinical trials.
• The regimen combines lenacapavir and islatravir into a once-weekly treatment designed to maintain viral suppression.
• The therapy performed as well as standard daily oral HIV treatments in late-stage studies.
• The companies plan to submit the results to regulators for approval.
• If approved, it could become the first once-weekly oral HIV treatment available to patients.

What This Means for Healthcare Marketers

The positive Phase 3 results highlight the pharmaceutical industry's continued shift toward therapies that improve both clinical outcomes and the patient experience. As treatment innovation increasingly focuses on convenience and adherence, companies that can demonstrate meaningful improvements in quality of life may gain a competitive advantage alongside traditional measures of efficacy and safety.

For healthcare marketers, the development illustrates the growing importance of communicating patient-centered innovation. Reduced dosing frequency can resonate with clinicians, patients, and payers by emphasizing ease of use, long-term adherence, and treatment persistence in addition to clinical performance.

For healthcare intelligence teams, the success of this once-weekly regimen signals continued momentum in long-acting HIV therapies. Tracking regulatory submissions, approval timelines, prescribing trends, and competitive developments in HIV treatment can provide valuable insight into how the market is evolving beyond conventional daily oral medications.